Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Autolus
Obecabtagene autoleucel is an autologous T cell immunotherapy made from the patient's own T cells genetically modified to express an anti-CD19 chimeric antigen receptor with a 4-1BB co-stimulatory domain. It binds CD19 on target cells, activating CD3-zeta signaling and killing CD19-expressing cells. It is used in relapsed or refractory B-cell precursor acute lymphoblastic leukemia and is studied in progressive multiple sclerosis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 23, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07053059 | Phase 2 | Acute Lymphocytic Leukemia (ALL) | Recruiting | AUTL |
| NCT04404660 | Phase 1/2 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Active not recruiting | AUTL |
| NCT07139743 | Phase 1 | Progressive Multiple Sclerosis | Recruiting | AUTL |
| NCT06799221 | N/A | Lymphoblastic Leukemia, Acute, Adult | Available | AUTL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Lymphocytic Leukemia (ALL)Progressive Multiple SclerosisRelapsed or Refractory B Cell Acute Lymphoblastic LeukemiaB Cell ALLLymphoblastic Leukemia, Acute, Adult
Updated Oct 8, 2026. Something wrong or missing? Report it on the AUTL page.
See AUTL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AUTL catalysts and pipeline →